The drug is indicated to treat breathing difficulty in patients with chronic obstructive pulmonary disease (COPD). Shipment of the product will begin immediately.
The company claims that the brand product had annual sales of approximately $265 million in the US for the twelve months ended September 30, 2007, based on IMS sales data.